Shimadzu Scientific Instruments Inc., a Shimadzu Group company, has opened a new research and development (R&D) facility in South San Francisco, California, a premier hub for pharmaceutical and life science R&D.

By establishing a lab in this location, SSI aims to deepen engagement with local researchers and institutions, gain a more precise understanding of customer needs, and accelerate the development of new products and technologies. Furthermore, SSI will actively collaborate with life science technology companies and AI-driven startups in the region, enabling a multifaceted approach to advancing its R&D activities.

The South San Francisco lab will focus on three key research areas:

• Analytical methods for drug delivery systems (DDS) including lipid nanoparticles (LNP) and adeno-associated viruses (AAV)
• New solutions for bioprocessing and preparative purification
• Cell culture solutions

The lab will be equipped with the triple quadrupole LCMS-8060RX, the Nexera ultra high-performance liquid chromatograph (UHPLC), the Nexera UC supercritical fluid chromatograph and the CF3-8030 centrifugal field-flow fractionation system.

Shimadzu Corporation has positioned North America as a strategic focus area and is committed to expanding its business. Through this South San Francisco lab, the company aims to establish itself as a market leader by delivering unique, next-generation solutions that contribute to the advancement of the industry.